CD19 and hemoglobinopathy: They compared their outcomes to a group of 40 patients with hemoglobinopathies who received CD34+-selected peripheral blood and bone marrow grafts (n = 32) or CD34+-selected peripheral blood and CD3+/CD19+-depleted bone marrow grafts (n = 8).